“In terms of funding for 4800 P3 trial we are asking various parties for support and are also considering doing the P3 together with Advaccine in order to save on costs.
Various NGOs [non-governmental organization] have expressed interest in our 4802 program; now, it can be a long road from interest to actual financial support but we are trying to do everything possible to minimize our burn rate. We hope that today’s [4802] pre print is the first step on that road.
We are working with our CRO [Clinical Research Organization] to select and prepare required documents to agencies of various nations where we are targeting our P3 trial. We are hoping to have additional news to share with you in the coming days and weeks.
Thank you for your continued interest. We are blessed to have such an informed investor as yourself on our corner.” 5/12/21
JK “ In late April, we announced that we would be implementing a global Phase 3 trial for INO-4800. We are working with funders and partners to achieve this plan and expect to start the trial this summer.
Additionally, we continue to be in discussions with a number of countries regarding INO-4800 advanced market procurement agreements [pre-orders] within the countries where the clinical trial sites are being planned. We look forward to proceeding with this Phase 3 trial this summer, and will have additional details to share regarding these efforts in the coming weeks. Most importantly, we remain on track to initiate our Phase 3 Segment of Innovate as we have previously stated.” 5/10 1Q21 CC
Market Data 
Markets 
AI
